Abstract
Extracellular vesicles (EVs), or exosomes, play a pivotal role in tumor growth and metastasis, such as in the case of Kaposi Sarcoma. By loading tumor-derived EVs with chemotherapeutic drugs, we noted that their pro-tumor/pro-angiogenic phenotype was converted into an anti-tumor phenotype in vivo. Drug concentration in EVs was significantly higher than in clinically approved liposome formulation, as retention was facilitated by the presence of miRNAs inside the natural EVs. This demonstrates a new mechanism by which to increase the payload capacity of nanoparticles. By exploiting the targeting preferences of tumor-derived EVs, chemotherapeutics can be directed to specifically poison the cells and the microenvironment that enables metastasis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 140-149 |
| Number of pages | 10 |
| Journal | ACS Bio and Med Chem Au |
| Volume | 2 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 20 2022 |
Keywords
- Kaposi's sarcoma
- drug delivery
- exosome
- extracellular vesicles
- virology
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Pharmaceutical Science
- Drug Discovery
Fingerprint
Dive into the research topics of 'Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS